Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 20, 2025 16:01 ET | Source: Travere Therapeutics, Inc.

Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Company to submit sNDA around the end of 1Q 2025 seeking traditional approval of FILSPARI® (sparsentan) for FSGS Net product sales of FILSPARI totaled $50 million in 4Q 2024; $132 million for full...
May 05, 2022 16:01 ET | Source: Travere Therapeutics, Inc.

Travere Therapeutics Reports First Quarter 2022 Financial Results

Submitted New Drug Application (NDA) for sparsentan in IgA nephropathy in March 2022 Results from Phase 1/2 COMPOSE Study of pegtibatinase in classical homocystinuria (HCU) presented at the Society...
December 15, 2021 07:00 ET | Source: Travere Therapeutics, Inc.

Travere Therapeutics Announces Positive Topline Results from the Ongoing Phase 1/2 COMPOSE Study of Pegtibatinase in Classical Homocystinuria

Treatment with highest dose pegtibatinase led to a clinically meaningful 55% mean reduction in total homocysteine from baseline and was generally well-tolerated after 12 weeks of treatment Results...
July 29, 2021 16:01 ET | Source: Travere Therapeutics, Inc.

Travere Therapeutics Reports Second Quarter 2021 Financial Results

Company expects to submit an application for conditional marketing authorization of sparsentan for FSGS in Europe before year-end 2021 Pivotal PROTECT Study of sparsentan in IgA nephropathy on track...
February 22, 2021 16:30 ET | Source: Travere Therapeutics, Inc.

Travere Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will present at the following upcoming virtual investor conferences in...
February 11, 2021 22:03 ET | Source: Travere Therapeutics, Inc.

Travere Therapeutics Announces Pricing of Public Offering of Common Stock

SAN DIEGO, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of an underwritten public offering of 6,550,000 shares of its common stock at a...